CHICAGO -- Adding an investigational TROP2-targeted antibody-drug conjugate (ADC) to first-line immunotherapy for PD-L1-positive non-small cell lung cancer (NSCLC) reduced the risk of disease ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...
Local recurrence was high in soft-tissue metastatic complete responders. However, patients who received radiation at bony ...
Leica Biosystems expands strategic collaboration with AstraZeneca & Daiichi Sankyo to develop an immunohistochemistry assay: Newcastle, UK Monday, June 1, 2026, 14:00 Hrs [IST] Le ...
A new report warns the world is heading towards a cancer care crisis, with cases sharply rising and the workforce failing to ...
Placing collagen tiles embedded with cesium-131 seeds into the surgical cavity when resecting brain metastases significantly ...
Oncology experts from all over the world will discuss the latest developments in care. The American Society of Clinical ...
Hyderabad- Nizam's Institute of Medical Sciences (NIMS), the first government-sector hospital in Telangana to offer cancer ...
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts ...
Medical artificial intelligence (AI) company Lunit announced on May 27 that it has launched an AI-based PD-L1 biomarker ...
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...
Janet S. Lee, MD (middle), a physician-scientist internationally recognized for groundbreaking research in acute lung injury, has been named the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results